EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

The effect of discontinuing hypertonic saline or dornase alfa on mucociliary clearance in elexacaftor/tezacaftor/ivacaftor treated people with cystic fibrosis: The SIMPLIFY-MCC Study

Scott H Donaldson, Timothy E Corcoran, Joseph M Pilewski, Beth L Laube, Peter Mogayzel, Agathe Ceppe, Jihong Wu, Kirby Zeman, Steven M Rowe, David P Nichols, Alex H Gifford, William D Bennett und 2 weitere

Journal of Cystic Fibrosis · 2024-05 · 23 (3) · 457-460

DOI: 10.1016/j.jcf.2024.02.003 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cystic Fibrosis, 2024-05. Verfasst von Scott H Donaldson und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and the Marsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: Scott_D…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Mucociliary Clearance, Benzodioxoles, Aminophenols. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, Cystic Fibrosis Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Many people with CF (pwCF) desire a reduction in inhaled treatment burden after initiation of elexacaftor/tezacaftor/ivacaftor. The randomized, open-label SIMPLIFY study showed that discontinuing hypertonic saline (HS) or dornase alfa (DA) was non-inferior to continuation of each treatment with respect to change in lung function over a 6-week period. In this SIMPLIFY substudy, we used gamma scintigraphy to determine whether discontinuation of either HS or DA was associated with deterioration in the rate of in vivo mucociliary clearance (MCC) in participants ≥12 years of age. While no significant differences in MCC endpoints were associated with HS discontinuation, significant improvement in whole and peripheral lung MCC was observed after discontinuing DA. These results suggest that pwCF on ETI with mild lung disease do not experience a subclinical deterioration in MCC that could later impact health outcomes after discontinuing HS, and in fact may benefit from improved MCC after stopping DA treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisMucociliary ClearanceBenzodioxolesAminophenolsDeoxyribonuclease IIndolesQuinolonesPyrazolesHumansMaleFemaleSaline Solution, HypertonicAdultAdolescentRecombinant ProteinsPyrrolesTreatment OutcomePyridinesYoung AdultChloride Channel AgonistsDrug CombinationsChildRespiratory Function TestsPyrrolidines

Stichwörter der Autor:innen

Clinical trialCystic fibrosisDornase alfaHypertonic salineMucociliary clearanceWithdrawal

Substanzen

BenzodioxolesSaline Solution, HypertonicAminophenolsdornase alfaDeoxyribonuclease IIndolesQuinolonesPyrazolesRecombinant Proteinselexacaftor

Autor:innen und Institutionen

  • Department of Medicine and the Marsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: Scott_Donaldson@med.unc.edu.
  • Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
  • Department of Pediatrics, Johns Hopkins University, Baltimore, MD, USA.
  • Department of Medicine and the Marsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Department of Medicine and the Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Seattle Children's Research Institute, Department of Pediatrics, University of Washington, Seattle, WA, USA.

Förderung

  • NIDDK NIH HHS
  • NCATS NIH HHS
  • Cystic Fibrosis Foundation
  • National Institutes of Health
  • NIDDK
  • NHLBI

Zitieren

APA

Donaldson, S. H., Corcoran, T. E., Pilewski, J. M., Laube, B. L., Mogayzel, P., Ceppe, A., Wu, J., Zeman, K., Rowe, S. M., Nichols, D. P., Gifford, A. H., Bennett, W. D., Mayer-Hamblett, N., & SIMPLIFY MCC Study teams (2024). The effect of discontinuing hypertonic saline or dornase alfa on mucociliary clearance in elexacaftor/tezacaftor/ivacaftor treated people with cystic fibrosis: The SIMPLIFY-MCC Study. Journal of Cystic Fibrosis, 23(3), 457-460. https://doi.org/10.1016/j.jcf.2024.02.003

Vancouver

Donaldson SH, Corcoran TE, Pilewski JM, Laube BL, Mogayzel P, Ceppe A, et al. The effect of discontinuing hypertonic saline or dornase alfa on mucociliary clearance in elexacaftor/tezacaftor/ivacaftor treated people with cystic fibrosis: The SIMPLIFY-MCC Study. Journal of Cystic Fibrosis. 2024;23(3):457-460. doi:10.1016/j.jcf.2024.02.003

BibTeX
@article{Donaldson2024,
  author = {Donaldson, Scott H and Corcoran, Timothy E and Pilewski, Joseph M and Laube, Beth L and Mogayzel, Peter and Ceppe, Agathe and Wu, Jihong and Zeman, Kirby and Rowe, Steven M and Nichols, David P and Gifford, Alex H and Bennett, William D and Mayer-Hamblett, Nicole and SIMPLIFY MCC Study teams, SIMPLIFY MCC Study teams},
  title = {The effect of discontinuing hypertonic saline or dornase alfa on mucociliary clearance in elexacaftor/tezacaftor/ivacaftor treated people with cystic fibrosis: The SIMPLIFY-MCC Study},
  journal = {Journal of Cystic Fibrosis},
  year = {2024},
  volume = {23},
  number = {3},
  pages = {457--460},
  doi = {10.1016/j.jcf.2024.02.003}
}
Kostenlos starten →